XML 60 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Income and Comprehensive Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Jan. 31, 2013
Jan. 31, 2012
Jan. 31, 2011
Net sales $ 1,399,719 $ 1,231,201 $ 1,063,404
Cost of goods sold 948,082 860,485 712,359
Gross profit 451,637 370,716 351,045
Selling, general and administrative expenses 341,242 [1] 277,019 248,380
Depreciation and amortization 9,907 7,473 5,733
Operating profit 100,488 86,224 96,932
Equity loss in joint venture 719 1,271  
Interest and financing charges, net 7,764 5,713 4,027
Income before income taxes 92,005 79,240 92,905
Income tax expense 35,436 29,620 36,223
Net income 56,569 49,620 56,682
Add: Loss attributable to noncontrolling interest 306    
Income attributable to G-III 56,875 49,620 56,682
Basic:      
Net income per common share $ 2.84 $ 2.51 $ 2.96
Weighted average number of shares outstanding 20,006 19,796 19,175
Diluted:      
Net income per common share $ 2.80 $ 2.46 $ 2.88
Weighted average number of shares outstanding 20,280 20,192 19,705
Net income attributable to G-III 56,875 49,620 56,682
Other comprehensive income:      
Foreign currency translation adjustments 3,519 23 17
Other comprehensive income 3,519 23 17
Comprehensive income $ 60,394 $ 49,643 $ 56,699
[1] Includes approximately $4.0 million of expenses and integration costs associated with the Vilebrequin acquistion which have been allocated across segments.